Srinivasan H.R., fondly known as Sri, is a member of its Board of Directors of Ecron Acunova. He brings 28 years of experience in Supply Chain Management and General Management.
Sri started his career as a Civil Servant in the Government of India. Post that, he successfully held several leadership roles including Executive Director of the Shriram Group, Managing Director of Sembcorp Logistics, Singapore, Managing Director of Temasek Capital, Singapore among others. He has served both on the State and Regional Councils of the Confederation of Indian Industry. He has also served as the Past President of TiE (The Indus Entrepreneurs), Chennai Chapter. In 2008, Sri was conferred with the CII Connect – “Entrepreneur of the Year” and the CII Tamil Nadu “Emerging Entrepreneur” award in 2010. He is a member of the YPO (Young Presidents Organisation).
Mr. Ravi is the Director of Ecron Acunova. His areas of work are Corporate Strategy, Corporate Finance, Compliance and Governance. He has over two decades of experience in Strategic planning, Business Process Re-engineering and Organization Change Management.
He is the Managing Director of Shriram Capital Limited which is the holding company of the USD 2 billion Shriram Group. Prior to this, he has held various senior assignments in the Shriram Group including Investment Servicing, IT and Corporate Service.
Mr. Ravi holds a Graduate Degree in Commerce and a Post Graduation in Management.
Since 1997, Marty has managed and led global business improvement assignments for clients like Bayer HealthCare, Pfizer, Johnson & Johnson, Roche, and many others in most areas of Pharmaceutical Drug Development and Supply Chain. He is one of the initiators and early leaders of pvnet®; Navitas’ network for Heads of Pharmacovigilance. Marty has held several leadership positions in Navitas (a TAKE Group Company) in Europe and USA. More recently he was the Head of Operations at Navitas, covering both the US and India geographies making significant contribution to the growth of the company. Marty is now the Managing Director for Ecron Acunova, Europe and will be based in Frankfurt.
As Chief Financial Officer Lalit is responsible for controllership, financial management and financial integration of business across services and geographies. Reporting to the Chairman of the Board, he manages shareholders expectations and oversees corporate governance and leads the M&A activities of the company.
Prior to joining EA, Lalit worked with Schneider Electric Company as Head of Finance of the Global Technology Centre and the project contracting business. He was part of global acquisition team and was instrumental in acquiring companies in India and Europe.
Lalit has over 15 years experience with companies like Siemens, Pacific Internet and Price Water House Cooper. His areas of expertise include strategic planning, fund management & harmonizing accounting practices to US GAAP, global IFRS standard and Indian GAAP.
Lalit is a Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant from USA.
Ayaaz is responsible for global delivery of services to all of our generic pharma customers.
Ayaaz has an extensive background in the generic pharmaceutical industry, including: Biopharmaceutics, Formulation Development, Clinical Pharmacokinetics, Clinical Development and Regulatory Affairs Prior to joining EA, Ayaaz worked in scientific and leadership positions for both major generic drug manufacturers such as Orchid Pharma and Ranbaxy and for major Indian BA/BE CROs.
Dr. Khan was sponsored by Ranbaxy Research Labs for a Senior Research Fellowship for Doctoral Research at Hamdard University. He has completed Ph. D in Pharmaceutical Medicine with specialization in Clinical Pharmacokinetics.
Natalya is responsible for global clinical studies in Central and Eastern Europe. She has experience in Marketing Authorization for drugs and devices in this region.
Natalya has served as Head of Eastern Europe for both bioRASI and Ergomed, where she managed a multifunctional team and built the operational structure of Russia and Eastern Europe. She has been international Project Manager for the large clinical studies for innovator sponsors as well as for global generic company’s clinical endpoint studies.
Natalya is an MD with clinical practice experience in general medicine. She was Senior Research Fellow at I.M. Sechenov Medical Academy Moscow. Natalya received PhD in internal medicine and her MBA in Management at the Russian Presidential Academy of National Economy and Public Administration in Moscow. She has authored 11 scientific publications and is a member of several medical and scientific societies.
With over 30 years’ experience in Clinical Research, Dr. Bluemner is responsible for protocol design (including statistical considerations), data management, statistical analysis, report writing, pharmacovigilance, and medical services.
Dr. Bluemner is credited with taking several drugs to market authorization in Europe. He has acted as Chief Statistician in regulatory meetings of EMA and US FDA at pre-IND stage, interim analysis, and final report defense. Key areas include oncology, cardiovascular, gastrointestinal, skin diseases, hormone replacement therapy and contrast agent imaging.
Prior to Ecron Acunova, Dr. Bluemner had been with the Max Planck Institute for Plasma Physics as Data Analyst and Programmer and as Director of Biometrics at Staticon. He is a member of the German Society for Medical Informatics, Biometrics and Epidemiology (GMDS) and International Biometric Society. He is also the recipient of E.W. Baader prize in Industrial Medicine.
Dr. Bluemner holds a MSc in Mathematics and an MD from Ludwig Maximilian University, Munich.
Sabine Kuehnau, PhD Director Marketing & Contracts
Sabine is responsible for contract issues. She has extensive experience in project management, proposal management, supervision of project performances, operational cost control, personnel affairs and day-to-day business. Sabine has been instrumental in the Company’s development from a national to an international CRO. She has managed more than 100 national and multi-national clinical projects (phase II -IV) in Europe. Key areas include rheumatology, gastroenterology, gynecology, pulmonology, dermatology etc.
Sabine began her career as a medical writer. She has been Production Manager according to AMG (German Drug Act) in 2006 and 2007.
Sabine is a member of the German Society for Pharmaceutical Medicine. She is an MSc in Biology and a PhD from University of Constance.
Dr. Arvind guides the company on operational excellence and in shaping the solution for clients in biosimilar development.
Dr. Arvind was Chief Operating Officer of Clinigene, a full service CRO and a Biocon subsidiary. He worked with Biocon for the past 10 years and has played an integral role in the clinical development of Biocon’s biosimilar pipeline and contributed to its strategic alliances with global majors.
Prior to joining Biocon, Arvind was a Consultant Physician with West Wales General Hospital, UK and held several prestigious positions at reputed hospitals in the UK. Earlier, he was the Medical Director of Mallya Hospital, Bangalore.
Dr. Arvind holds a FRCP from the Royal Colleges of Physicians, London & Glasgow, MD from Bangalore Medical College, MBBS from St. Johns Medical College and MBA from the University of Birmingham.